Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 janv. 2020 08h00 HE | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform

OV101 (gaboxadol) in Neurodevelopmental Disorders: Topline Results From Pivotal Phase 3 NEPTUNE Trial in Angelman Syndrome Expected in Mid-2020Results From Phase 2 Signal-Finding ROCKET Trial and SKY...
26 nov. 2019 08h00 HE | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Participate at the 31st Annual Piper Jaffray Healthcare Conference

NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
18 nov. 2019 16h05 HE | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Appoints Jason Tardio as Chief Commercial Officer

Seasoned CNS and Rare Disease Commercial Executive Further Strengthens Executive Management Team NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a...
08 nov. 2019 08h00 HE | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Third Quarter 2019 Financial Results and Recent Progress

Announced Positive Initial Results from the Ongoing ENDYMION trial with OV935 (Soticlestat) in Rare Epilepsies; Sustained and Progressively-Improving Median Seizure Frequency Reduction with Prolonged...
01 nov. 2019 08h00 HE | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Senior Management Promotions in Preparation for Multiple Data Readouts Expected in 2020

Amit Rakhit, M.D., MBA, Promoted to President Timothy Daly Promoted to Executive Vice President, Finance NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a...
04 oct. 2019 08h30 HE | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock

NEW YORK, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare...
03 oct. 2019 16h01 HE | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock

NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare...
23 sept. 2019 07h00 HE | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Positive Initial Data from Ongoing ENDYMION Open-Label Extension Trial of Soticlestat in People with Rare Epilepsies

Sustained and Progressively-Improving Median Seizure Frequency Reduction Reaching 84-90% with Prolonged Treatment of Soticlestat in this Difficult-to-Treat Patient Population Soticlestat Continues to...
12 sept. 2019 08h00 HE | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 NEPTUNE Trial of OV101 for the Treatment of Angelman Syndrome

NEW YORK, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
09 sept. 2019 08h00 HE | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...

Page précédente